Illumina stock is trading -13.5% below its average target price of $154.86 after marking a 2.9% during today's morning session. Analysts are giving the Large-Cap Medical Specialities company an average rating of buy and target prices ranging from $85.0 to $258.0 per share.
Illumina's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 3.5%. The stock's short ratio is 2.8. The company's insiders own 0.27% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 94.5%. In conclusion, we believe there is mixed market sentiment regarding Illumina.
Institutions Invested in Illumina
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-12-31 | Vanguard Group Inc | 11% | 18,178,513 | $2,435,099,136 |
| 2023-12-31 | Blackrock Inc. | 8% | 13,302,999 | $1,782,000,616 |
| 2023-12-31 | Edgewood Management Llc | 4% | 6,878,495 | $921,407,445 |
| 2023-12-31 | State Street Corporation | 4% | 6,723,616 | $900,660,659 |
| 2023-12-31 | Baillie Gifford and Company | 3% | 5,275,769 | $706,714,599 |
| 2023-12-31 | Loomis Sayles & Company, LP | 3% | 4,424,688 | $592,708,211 |
| 2023-12-31 | Janus Henderson Group PLC | 3% | 4,402,380 | $589,719,947 |
| 2023-12-31 | Morgan Stanley | 2% | 3,698,229 | $495,395,538 |
| 2023-12-31 | Geode Capital Management, LLC | 2% | 3,634,176 | $486,815,331 |
| 2023-12-31 | Wellington Management Group, LLP | 2% | 3,239,021 | $433,882,421 |
